We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen, Genentech Await Del. Ruling In Biosimilar IP Row

Law360, Los Angeles (January 11, 2018, 6:13 PM EST) -- A California federal judge on Thursday tentatively paused Amgen’s suit seeking to invalidate more than two dozen patents related to Genentech’s cancer treatment Avastin, saying he wanted to see whether a Delaware court will transfer infringement actions that Genentech has filed over Amgen’s biosimilar version of the drug.

U.S. District Court Judge George Wu held a hearing on Genentech’s motion to dismiss Amgen’s suit seeking a declaration that 27 patents related to Avastin are invalid, unenforceable and not infringed by Amgen’s biologic, which has been approved by...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Amgen Inc v. Genentech, Inc. et al


Case Number

2:17-cv-07349

Court

California Central

Nature of Suit

Patent

Judge

George H. Wu

Date Filed

October 6, 2017

Law Firms

Companies

Government Agencies

Patents

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.